Cargando…

Correction: Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896243/ https://www.ncbi.nlm.nih.gov/pubmed/36725086 http://dx.doi.org/10.1136/jitc-2022-005518corr1

Ejemplares similares

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections
por: van Puffelen, Jelmer H, et al.
Publicado: (2023)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Correction to: Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
por: Wadhwani, Aman, et al.
Publicado: (2019)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
por: Veeratterapillay, Rajan, et al.
Publicado: (2016)

Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer
por: Mohammed, Azharuddin, et al.
Publicado: (2017)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

Intravesical chemotherapy in non-muscle-invasive bladder cancer
por: Porten, Sima P., et al.
Publicado: (2015)

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study
por: Ji, Niannian, et al.
Publicado: (2021)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non–muscle-invasive bladder cancer patients
por: Tae, Bum Sik, et al.
Publicado: (2017)

Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer
por: Pak, Sahyun, et al.
Publicado: (2021)

Factors effecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG
por: Kashif Khan, Muhammad, et al.
Publicado: (2014)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
por: Seegobin, Karan, et al.
Publicado: (2017)

Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis
por: Del Giudice, Francesco, et al.
Publicado: (2022)

Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer—analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I)
por: Thyavihally, Yuvaraja B., et al.
Publicado: (2022)

Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
por: Ali-El-Dein, Bedeir, et al.
Publicado: (2013)

Re: Factors affecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG
por: Huang, Haichao, et al.
Publicado: (2014)

Intravesical gemcitabine as bladder‐preserving treatment for BCG unresponsive non‐muscle‐invasive bladder cancer. Results from a single‐arm, open‐label study
por: Hurle, Rodolfo, et al.
Publicado: (2020)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
por: Bhat, Suresh, et al.
Publicado: (2015)

Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer
por: Thiel, Tomas, et al.
Publicado: (2018)

Complete response to intravesical gemcitabine in non‐muscle invasive bladder cancer patient after BCG failure: A case report and literature review
por: Nahhat, Fouad, et al.
Publicado: (2022)

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer
por: Douglass, Laura, et al.
Publicado: (2016)

Device-assisted intravesical therapy for non-muscle invasive bladder cancer
por: Hendricksen, Kees
Publicado: (2019)

P58. Can T-cells predict response to intravesical BCG immunotherapy in high-risk non-invasive bladder cancer
por: Jallad, S, et al.
Publicado: (2014)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder Cancer
por: Mackel, Charles E, et al.
Publicado: (2016)

Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma
por: Doroud, Delaram, et al.
Publicado: (2022)

Thulium Laser Resection of Bladder Tumors vs. Conventional Transurethral Resection of Bladder Tumors for Intermediate and High Risk Non-Muscle-Invasive Bladder Cancer Followed by Intravesical BCG Immunotherapy
por: Liu, Zheng, et al.
Publicado: (2021)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)
por: Hayne, Dickon, et al.
Publicado: (2015)

A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer
por: Joshua, Julie Mariam, et al.
Publicado: (2019)

Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review
por: Han, Mi Ah, et al.
Publicado: (2021)

Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG
Publicado: (2015)

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
por: Huang, Jeffrey, et al.
Publicado: (2017)

Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer
por: Vilares, Ana T., et al.
Publicado: (2022)

Intravesical BCG in bladder cancer induces innate immune responses against SARS-CoV-2
por: Pichler, Renate, et al.
Publicado: (2023)

Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study
por: Oughton, Jamie B, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nhfe0t58kj9e6kelbfe9ng1ovl